-25%

SS-31 50 mg

Original price was: 159,99 €.Current price is: 119,99 €. with VAT

SS-31 (Elamipretide) is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH₂, developed in the laboratories of Szeto and Schiller (Cornell). It selectively binds to cardiolipin in the inner mitochondrial membrane, thereby stabilizing the crystal structure, reducing the production of reactive oxygen species (ROS) at the source, and increasing ATP output. In September 2025, it received FDA approval for Barth syndrome, becoming the first mitochondria-targeted peptide in history.

Purity ≥ 98% – Each batch verified by HPLC; COA available upon request
Freeze-dried powder, store at −20 °C
Shipped within 48 hours

Only 10 left in stock

Dosage calculator

Quantity discount

Quantity	Price	% Discount
7+	107,99 €	10%
4+	113,99 €	5%

Category: Research on Longevity and the Slowing of Aging

All products are sold exclusively for the purpose of scientific research and development.
The chemical substances may not be used as a medicine, drug, active substance, medical device, cosmetic product, substance for the manufacture of a cosmetic product, or as a substance for human consumption, i.e. as a food or nutritional supplement, or in any other similar way on humans or animals.

All customers MUST be at least 18 years of age to purchase our products.

Laboratory-tested

Fast and Discreet Shipping

Purity Guarantee

98%+

Description

SS-31 50 mg (Elamipretide) – A Mitochondria-Targeted Tetrapeptide for Research on Cellular Energy Metabolism

⚠️ Warning: This product is intended exclusively for scientific research and laboratory use. It is not intended for human or veterinary consumption, nor for the diagnosis, treatment, or prevention of any diseases. Sale restricted to individuals 18 years of age or older.
SS-31 (also known as Elamipretide, Bendavia, or MTP-131) is a synthetic, cell-permeable tetrapeptide with the unique ability to selectively accumulate in the inner mitochondrial membrane. It was developed by Prof. Hazel Szeto and Peter Schiller at Cornell Weill Medical College and is in clinical development by Stealth BioTherapeutics. In September 2025, it received FDA approval for Barth syndrome, becoming the first-ever mitochondria-targeted peptide to receive regulatory approval.

Chemical Identity

Parameter	Value
Other names	Elamipretide, Bendavia, MTP-131
Sequence	D-Arg-Dmt-Lys-Phe-NH₂
CAS Number	736992-21-5
Molecular weight	~640 Da
Form	Freeze-dried powder
Purity	≥98% (HPLC)

Mechanism of action — cardiolipin binding

The mechanism of action of SS-31 is fundamentally different from that of most research peptides: its target is not a cell surface receptor, but cardiolipin —an anionic phospholipid unique to the inner mitochondrial membrane.

Electrostatic guidance: the peptide’s alternative aromatic-cationic motif electrostatically attracts it to the highly negative potential of the inner mitochondrial membrane
Binding to cardiolipin: SS-31 selectively binds to cardiolipin, thereby concentrating directly in the electron transport chain
Stabilization of the crystal structure: prevents the peroxidation of cardiolipin → preserves the integrity of mitochondrial crystals and ETC supercomplexes
ROS reduction at the source: Unlike antioxidants, which scavenge free radicals only after they have been generated, SS-31 prevents excessive ROS production by maintaining an efficient flow of electrons
Increased ATP output: optimization of ETC function → higher ATP production in cells under metabolic stress

Areas of Preclinical and Clinical Research

Mitochondrial cardiomyopathy and heart failure

In a Phase 2 clinical trial for HFrEF (heart failure with reduced ejection fraction), SS-31 demonstrated a 10–15% improvement in peak VO₂ after 4 weeks of IV administration. For Barth syndrome (a genetic cardiomyopathy caused by cardiolipin defects), improvements were observed in the 6-minute walk test and cardiac stroke volume.

Renal Protection

Preclinical models of renal ischemia-reperfusion have demonstrated the preservation of mitochondrial function and a reduction in tubular apoptosis in cell cultures and animal models.

Research on Aging and Mitochondrial Dysfunction

With age, cardiolipin oxidation disrupts ETC supercomplexes—SS-31 is being investigated in animal models of aging as a tool for preserving mitochondrial biogenesis and skeletal muscle function.

Neuroprotection

In models of oxidative stress in neuronal cells, SS-31 protects against apoptosis, making it a subject of research into neurodegenerative diseases.

Ischemic protection (preclinical)

Models of ischemia-reperfusion injury (heart, kidneys, brain)—SS-31 investigated as a mitochondrial protector during reperfusion.

Clinical Status (July 2026)

Indications	Phase	Status
Barth Syndrome	Approved by the FDA	✅ Approved in September 2025 (Elamipretide)
HFrEF (heart failure)	Stage 2/3	In progress
Primary Mitochondrial Myopathy	Phase 2	In progress
Age-related macular degeneration	Stage 2	In progress

SS-31, available at jacked.sk, is a research-grade product (not a clinical product from Stealth BioTherapeutics) intended exclusively for preclinical laboratory research.

Technical Specifications

Parameter	Value
Contents per package	50 mg
Form	Freeze-dried powder (vial)
Purity	≥98% (HPLC-verified)
Storage – freeze-dried	−20 °C, protect from light
Storage – after reconstitution	2–8 °C, use within 14 days
Recommended solvent	0.9% NaCl saline solution or sterile water
Intended Use	Exclusively preclinical/laboratory research
Age Restriction	18+

Frequently Asked Questions About SS-31 (FAQ)

What is SS-31, and why is it of interest to researchers?

SS-31 (Elamipretide) is the first mitochondria-targeted peptide to receive FDA approval (Barth syndrome, September 2025). It is of scientific interest due to its unique ability to bind cardiolipin directly to the inner mitochondrial membrane—without receptor mediation.

What is the difference between SS-31 and common antioxidants?

Common antioxidants (vitamins C and E) neutralize free radicals only after they have been formed. SS-31 prevents the excessive production of ROS by optimizing the efficiency of the electron transport chain at its source.

Is SS-31 the same as Elamipretide?

Yes. SS-31 is the scientific designation (Szeto-Schiller peptide 31), Elamipretide is the generic pharmaceutical name, and Bendavia is the brand name. The Stealth BioTherapeutics clinical product is a regulated therapeutic agent—SS-31 on jacked.sk is intended solely for research purposes.

How should SS-31 be stored?

Store the freeze-dried vial at −20 °C, protected from light and moisture. After reconstitution, store at 2–8 °C and use within 14 days. Use the dosing calculator to determine the exact volume of solvent.

Is the SS-31 intended for human use?

No. This product is intended solely for scientific research and laboratory use. It is not intended for human or veterinary use.

⚠️ Final Disclaimer

SS-31 / Elamipretide, available at jacked.sk, is a research compound intended exclusively for laboratory and preclinical studies. It is not approved in the EU for human use. It is not a drug, dietary supplement, or diagnostic agent. The seller is not liable for any use contrary to these terms and conditions.